Literature DB >> 33069310

Characterising neuropsychiatric disorders in patients with COVID-19 - Authors' reply.

Aravinthan Varatharaj1, Thomas A Pollak2, Timothy R Nicholson2, Jonathan P Coles3, Laura A Benjamin4, Alan Carson5, Rhys H Thomas6, Benedict D Michael7.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 33069310      PMCID: PMC7561324          DOI: 10.1016/S2215-0366(20)30420-X

Source DB:  PubMed          Journal:  Lancet Psychiatry        ISSN: 2215-0366            Impact factor:   27.083


× No keyword cloud information.
We thank Dorothy Wade and colleagues and Mark Oldham and colleagues for their recognition of the cross-speciality effort of members of the UK's major professional neuroscience bodies who undertook this challenging UK-wide study during the exponential phase of the COVID-19 pandemic. We also welcome the involvement of geriatricians and psychologists in future research. We agree that delirium is common, especially in severe infections and in the intensive care unit. As stated in our Article, we acknowledge that the study might have not recorded all such cases. Changes in mental status with clear and recognised risk factors were not the focus of this study (eg, those explained by severe systemic illness and associated with dementia or cognitive impairment). We agree that if such commonly observed complications were included, they might have substantially increased the number of patients recruited, mirroring the situation in other critical illnesses. In this situation, the burden of CNS complications arising from COVID-19 would be even greater than we found in our study. We agree that consistent terminology is needed for the many causes of alterations of mental state and an improved understanding of the underlying pathophysiology that should determine this is urgently required. We acknowledge the position paper on a proposed terminology of these complex presentations and, appreciating the value of multidisciplinary approaches, would support involvement of the professional bodies in relevant areas of psychiatry, neuropsychiatry, and neurological infection, as well as patient and public involvement, in future iterations. We understand the motivations for wishing to avoid the term altered mental status. However, we carefully considered the information notified and took an ontological approach for over-arching terms that include disturbances of mental state occurring without the clinical features of delirium (including isolated psychosis, catatonia, anxiety, and mania). Our study was done with clear a-priori clinical case definitions, such as encephalitis, to support the experienced clinicians reporting cases, reflecting national guidelines, and it was clearly intended to report acute presentations. We took a strong view that the knowledge of the bedside specialist clinician assessing the patient was inherently valuable, and that rediagnosing patients from a distance would be neither wise nor accurate. Psychiatrists, for example, commonly differentiate psychosis from psychotic symptoms occurring as part of delirium; indeed, it is routine practice to provide reassurance that new-onset psychosis is actually delirium and should resolve. Even in 1918, both psychiatrists and neurologists, including Menninger and von Economo, were careful to distinguish patients with primary brain dysfunction or disease from those whose symptoms were explained by systemic processes. Our study was designed from the outset in a three-stage approach: stage 1 is the core dataset provided by clinicians during the pandemic; stage 2 is detailed clinical data collection; and stage 3 is to evaluate disease mechanisms, including viral neurotropism and para-infectious or post-infectious innate and adaptive immune responses, polygenic risk, endothelial dysfunction, and coagulopathy. Stages 2 and 3 are underway. Substantial evidence exists that non-CNS infection can cause neuropsychiatric presentations in the absence of delirium, which has now been shown with severe acute respiratory syndrome coronavirus 2 infection. We therefore strongly disagree that all acute COVID-associated neuropsychiatric phenomenology can be explained by delirium. Full detailed analysis of stage 2 and 3 data from this study is underway and the multidisciplinary authors will continue to be guided by the clinical data and underlying disease mechanisms. Altered mental status will continue to remain an important term in our global WHO and World Federation of Neurology studies of COVID-19 and the brain until these mechanisms are elucidated. We welcome ongoing discussions and collaborations on the intersections of these complex concepts and disorders as this important work progresses. For the guideline from the Faculty of Intensive Care Medicine see https://www.ficm.ac.uk/sites/default/files/ficm_rehab_provisional_guidance.pdf
  4 in total

1.  A Nationwide Study in Denmark of the Association Between Treated Infections and the Subsequent Risk of Treated Mental Disorders in Children and Adolescents.

Authors:  Ole Köhler-Forsberg; Liselotte Petersen; Christiane Gasse; Preben B Mortensen; Soren Dalsgaard; Robert H Yolken; Ole Mors; Michael E Benros
Journal:  JAMA Psychiatry       Date:  2019-03-01       Impact factor: 21.596

2.  Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study.

Authors:  Aravinthan Varatharaj; Naomi Thomas; Mark A Ellul; Nicholas W S Davies; Thomas A Pollak; Elizabeth L Tenorio; Mustafa Sultan; Ava Easton; Gerome Breen; Michael Zandi; Jonathan P Coles; Hadi Manji; Rustam Al-Shahi Salman; David K Menon; Timothy R Nicholson; Laura A Benjamin; Alan Carson; Craig Smith; Martin R Turner; Tom Solomon; Rachel Kneen; Sarah L Pett; Ian Galea; Rhys H Thomas; Benedict D Michael
Journal:  Lancet Psychiatry       Date:  2020-06-25       Impact factor: 27.083

3.  Updated nomenclature of delirium and acute encephalopathy: statement of ten Societies.

Authors:  Arjen J C Slooter; Wim M Otte; John W Devlin; Rakesh C Arora; Thomas P Bleck; Jan Claassen; Matthew S Duprey; E Wesley Ely; Peter W Kaplan; Nicola Latronico; Alessandro Morandi; Karin J Neufeld; Tarek Sharshar; Alasdair M J MacLullich; Robert D Stevens
Journal:  Intensive Care Med       Date:  2020-02-13       Impact factor: 17.440

4.  Psychotic symptoms in COVID-19 patients. A retrospective descriptive study.

Authors:  A Parra; A Juanes; C P Losada; S Álvarez-Sesmero; V D Santana; I Martí; J Urricelqui; D Rentero
Journal:  Psychiatry Res       Date:  2020-06-24       Impact factor: 3.222

  4 in total
  5 in total

1.  Spectrum, risk factors and outcomes of neurological and psychiatric complications of COVID-19: a UK-wide cross-sectional surveillance study.

Authors:  Amy L Ross Russell; Marc Hardwick; Athavan Jeyanantham; Laura M White; Saumitro Deb; Girvan Burnside; Harriet M Joy; Craig J Smith; Thomas A Pollak; Timothy R Nicholson; Nicholas W S Davies; Hadi Manji; Ava Easton; Stephen Ray; Michael S Zandi; Jonathan P Coles; David K Menon; Aravinthan Varatharaj; Beth McCausland; Mark A Ellul; Naomi Thomas; Gerome Breen; Stephen Keddie; Michael P Lunn; John P S Burn; Graziella Quattrocchi; Luke Dixon; Claire M Rice; George Pengas; Rustam Al-Shahi Salman; Alan Carson; Eileen M Joyce; Martin R Turner; Laura A Benjamin; Tom Solomon; Rachel Kneen; Sarah Pett; Rhys H Thomas; Benedict D Michael; Ian Galea
Journal:  Brain Commun       Date:  2021-07-22

Review 2.  Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses.

Authors:  Peter Riederer; Volker Ter Meulen
Journal:  J Neural Transm (Vienna)       Date:  2020-07-28       Impact factor: 3.575

Review 3.  Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature.

Authors:  Maziar Emamikhah; Mansoureh Babadi; Mehrnoush Mehrabani; Mehdi Jalili; Maryam Pouranian; Peyman Daraie; Fahimeh Mohaghegh; Sharmin Aghavali; Maryam Zaribafian; Mohammad Rohani
Journal:  J Neurovirol       Date:  2021-01-25       Impact factor: 2.643

4.  Coronavirus infections from 2002 to 2021: neuropsychiatric manifestations.

Authors:  Amber Barthorpe; Jonathan P Rogers
Journal:  Sleep Med       Date:  2021-12-08       Impact factor: 4.842

Review 5.  The Impact of the COVID-19 Virus Pandemic on the Incidence of First Psychotic Spectrum Disorders.

Authors:  Kacper Łoś; Joanna Kulikowska; Napoleon Waszkiewicz
Journal:  Int J Environ Res Public Health       Date:  2022-03-22       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.